Peripheral and central effects of melatonin on blood pressure regulation

International Journal of Molecular Sciences

Volumn 15, Issue 10, 2014, Pages 17920-17937

  Pechanova, Olga ^a,b   Paulis, Ludovit ^a,b   Simko, Fedor ^b,c  

^a INSTITUTE OF CHEMISTRY   (Slovakia)

^b Physics and Informatics   (Slovakia)

^c INSTITUTE OF EXPERIMENTAL ENDOCRINOLOGY   (Slovakia)

Author keywords

Central nervous system (CNS); Hypertension; Melatonin; MT1 and MT2 receptors; Reactive oxygen species (ROS)

Indexed keywords

4 AMINOBUTYRIC ACID; ANGIOTENSIN RECEPTOR; BETA ADRENERGIC RECEPTOR; CALMODULIN; CYCLIC AMP; ENDOTHELIAL NITRIC OXIDE SYNTHASE; G PROTEIN COUPLED RECEPTOR; GLYCOPROTEIN GP 91; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MELATONIN; MELATONIN 1 RECEPTOR; MELATONIN 2 RECEPTOR; NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; NITRIC OXIDE; PINEAL BODY HORMONE; PROTEIN P47; REACTIVE OXYGEN METABOLITE;

ADAPTIVE BEHAVIOR; ADRENERGIC SYSTEM; ANTIHYPERTENSIVE ACTIVITY; ANTIOXIDANT ACTIVITY; AUTONOMIC NERVOUS SYSTEM; BLOOD PRESSURE REGULATION; CALCIUM METABOLISM; CENTRAL NERVOUS SYSTEM; CIRCADIAN RHYTHM; DOWN REGULATION; ENDOTHELIAL DYSFUNCTION; HORMONE ACTION; HUMAN; HYPERTENSION; IMMOBILIZATION STRESS; INFLAMMATION; MITOCHONDRIAL ENERGY TRANSFER; NERVOUS SYSTEM FUNCTION; NEUROLOGIC DISEASE; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PERIPHERAL NERVOUS SYSTEM; PLEIOTROPY; PROTEIN EXPRESSION; QUESTIONNAIRE; REVIEW; SCAVENGING SYSTEM; SIGNAL TRANSDUCTION; SYMPATHETIC TONE; VASOCONSTRICTION; BLOOD; BLOOD PRESSURE; METABOLISM; PATHOLOGY; PHYSIOLOGY;

BLOOD PRESSURE; CENTRAL NERVOUS SYSTEM; HUMANS; HYPERTENSION; MELATONIN; REACTIVE OXYGEN SPECIES; RECEPTOR, MELATONIN, MT1; RECEPTOR, MELATONIN, MT2;

EID: 84907842543     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms151017920     Document Type: Review

References (127)

1. Paton, J. F.; Waki, H. Is neurogenic hypertension related to vascular inflammation of the brainstem? Neurosci. Biobehav. Rev. 2009, 33, 89-94.
2. Waki, H.; Gouraud, S. S.; Maeda, M.; Raizada, M. K.; Paton, J. F. Contributions of vascular inflammation in the brainstem for neurogenic hypertension. Respir. Physiol. Neurobiol. 2011, 178, 422-428.
3. Waki, H.; Gouraud, S. S.; Maeda, M.; Paton J. F. Specific inflammatory condition in nucleus tractus solitarii of the SHR: Novel insight for neurogenic hypertension? Auton. Neurosci. 2008, 142, 25-31.
4. Pevet, P.; Challet, E. Melatonin: Both master clock output and internal time-giver in the circadian clocks network. J. Physiol. Paris 2011, 105, 170-182.
5. Hardeland, R.; Cardinali, D. P.; Srinivasan, V.; Spence, D. W.; Brown, G. M.; Pandi-Perumal, S. R. Melatonin-A pleiotropic, orchestrating regulator molecule. Prog. Neurobiol. 2011, 93, 350-384.
6. Reiter, R. J.; Rosales-Corral, S.; Coto-Montes, A.; Boga, J. A.; Tan, D. X.; Davis, J. M.; Konturek, P. C.; Konturek, S. J.; Brzozowski. T. The photoperiod, circadian regulation and chronodisruption: The requisite interplay between the suprachiasmatic nuclei and the pineal and gut melatonin. J. Physiol. Pharmacol. 2011, 62, 269-274.
7. Reiter, R. J.; Tan, D. X.; Rosales-Corral, S.; Manchester, L. C. The universal nature, unequal distribution and antioxidant functions of melatonin and its derivatives. Mini Rev. Med. Chem. 2013, 13, 373-384.
8. Zeman, M.; Herichova, I. Melatonin and clock genes expression in the cardiovascular system. Front. Biosci. 2013, 5, 743-753.
9. Dominguez-Rodriguez, A.; Abreu-Gonzalez, P.; Sanchez-Sanchez, J. J.; Kaski, J. C.; Reiter, R. J. Melatonin and circadian biology in human cardiovascular disease. J. Pineal Res. 2010, 49, 14-22.
10. Dominguez-Rodriguez, A.; Abreu-Gonzalez, P.; Arroyo-Ucar, E., Reiter, R. J. Decreased level of melatonin in serum predicts left ventricular remodelling after acute myocardial infarction. J. Pineal Res. 2012, 53, 319-323.
11. Dominguez-Rodriguez, A.; Abreu-Gonzalez, P.; Reiter, R. J. Melatonin and cardiovascular disease: Myth or reality? Rev. Esp. Cardiol. 2012, 65, 215-218.
12. Reiter, R. J.; Tan, D. X.; Fuentes-Broto, L. Melatonin: A multitasking molecule. Prog. Brain Res. 2010, 181, 127-151.
13. Simko, F.; Paulis, L. Melatonin as a potential antihypertensive treatment. J. Pineal Res. 2007, 42, 319-322.
14. Simko, F.; Pechanova, O. Recent trends in hypertension treatment: Perspectives from animal studies. J. Hypertens. 2009, 27, S1-S4.
15. Tan, D. X.; Hardeland, R.; Manchester, L. C.; Rosales-Corral, S.; Coto-Montes, A.; Boga, J. A.; Reiter, R. J. Emergence of naturally occurring melatonin isomers and their proposed nomenclature. J. Pineal Res. 2012, 53, 113-121.
16. Galano, A.; Tan, D. X.; Reiter, R. J. On the free radical scavenging activities of melatonin's metabolites, AFMK and AMK. J. Pineal Res. 2013, 54, 245-257.
17. Agil, A.; Reiter, R. J.; Jiménez-Aranda, A.; Ibán-Arias, R.; Navarro-Alarcón, M.; Marchal, J. A.; Adem, A.; Fernández-Vázquez G. Melatonin ameliorates low-grade inflammation and oxidative stress in young Zucker diabetic fatty rats. J. Pineal Res. 2013, 54, 381-388.
18. Venegas, C.; García, J. A.; Doerrier, C.; Volt, H.; Escames, G.; López, L. C.; Reiter, R. J.; Acuña-Castroviejo, D. Analysis of the daily changes of melatonin receptors in the rat liver. J. Pineal Res. 2013, 54, 313-321.
19. Simko, F.; Paulis, L. Antifibrotic effect of melatonin-perspective protection in hypertensive heart disease. Int. J. Cardiol. 2013, 168, 2876-2877.
20. Simko, F.; Reiter, R. J.; Pechanova, O.; Paulis, L. Experimental models of melatonin-deficient hypertension. Front. Biosci. 2013, 18, 616-625.
21. Favero, G.; Rodella, L. F.; Reiter, R. J.; Rezzani, R. Melatonin and its atheroprotective effects: A review. Mol. Cell. Endocrinol. 2014, 382, 926-937.
22. Rosen, J.; Than, N. N.; Koch, D.; Poeggeler, B.; Laatsch, H.; Hardeland, R. Interactions of melatonin and its metabolites with the ABTS cation radical: Extension of the radical scavenger cascade and formation of a novel class of oxidation products, C2-substituted 3-indolinones. J. Pineal Res. 2006, 41, 374-381.
23. Alonso-Alconada, D.; Alvarez, A.; Arteaga, O.; Martínez-Ibargüen, A.; Hilario, E. Neuroprotective effect of melatonin: A novel therapy against perinatal hypoxia-ischemia. Int. J. Mol. Sci. 2013, 14, 9379-9395.
24. Acuna-Castroviejo, D.; Martin, M.; Macias, M.; Escames, G.; Leon, J.; Khaldy, H.; Reiter, R. J. Melatonin, mitochondria, and cellular bioenergetics. J. Pineal Res. 2001, 30, 65-74.
25. Tomas-Zapico, C.; Coto-Montes, A. A proposed mechanism to explain the stimulatory effect of melatonin on antioxidative enzymes. J. Pineal Res. 2005, 39, 99-104.
26. Reiter, R. J.; Tan, D. X.; Osuna, C.; Gitto, E. Actions of melatonin in the reduction of oxidative stress. A review. J. Biomed. Sci. 2000, 7, 444-458.
27. Kojsova, S.; Jendekova, L.; Zicha, J.; Kunes, J.; Andriantsitohaina, R.; Pechanova, O. The effect of different antioxidants on nitric oxide production in hypertensive rats. Physiol. Res. 2006, 55, S3-S16.
28. Pechanova, O.; Simko, F. Chronic antioxidant therapy fails to ameliorate hypertension: Potential mechanisms behind. J. Hypertens. Suppl. 2009, 27, S32-S36.
29. Paulis, L.; Simko, F.; Laudon, M. Cardiovascular effects of melatonin receptor agonists. Expert Opin. Investig. Drugs 2012, 21, 1661-1678.
30. Slominski, R. M.; Reiter, R. J.; Schlabritz-Loutsevitch, N.; Ostrom, R. S.; Slominski, A. T. Melatonin membrane receptors in peripheral tissues: Distribution and functions. Mol. Cell. Endocrinol. 2012, 351, 152-166.
31. Nosjean, O.; Ferro, M.; Coge, F.; Beauverger, P.; Henlin, J. M.; Lefoulon, F.; Fauchere, J. L.; Delagrange, P.; Canet, E.; Boutin, J. A. Identification of the melatonin-binding site MT3 as the quinone reductase 2. J. Biol. Chem. 2000, 275, 31311-31317.
32. Nosjean, O.; Nicolas, J. P.; Klupsch, F.; Delagrange, P.; Canet, E.; Boutin, J. A. Comparative pharmacological studies of melatonin receptors: MT1, MT2 and MT3/QR2. Tissue distribution of MT3/QR2. Biochem. Pharmacol. 2001, 61, 1369-1379.
33. Luchetti, F.; Canonico, B.; Betti, M.; Arcangeletti, M.; Pilolli, F.; Piroddi, M.; Canesi, L.; Papa, S.; Galli, F. Melatonin signaling and cell protection function. FASEB J. 2010, 24, 3603-3624.
34. Krause, D. N.; Barrios, V. E.; Duckles, S. P. Melatonin receptors mediate potentiation of contractile responses to adrenergic nerve stimulation in rat caudal artery. Eur. J. Pharmacol. 1995, 276, 207-213.
35. Ting, K. N.; Dunn, W. R.; Davies, D. J.; Sugden, D.; Delagrange, P.; Guardiola-Lemaître, B.; Scalbert, E.; Wilson, V. G. Studies on the vasoconstrictor action of melatonin and putative melatonin receptor ligands in the tail artery of juvenile Wistar rats. Br. J. Pharmacol. 1997, 122, 1299-1306.
36. Girouard, H.; Chulak, C. H.; Lejossec, M.; Lamontagne, D.; de Champlain, J. Vasorelaxant effects of the chronic treatment with melatonin on mesenteric artery and aorta of spontaneously hypertensive rats. J. Hypertens. 2001, 19, 1369-1377.
37. Weekley, L. B. Melatonin-induced relaxation of rat aorta: Interaction with adrenergic agonists. J. Pineal Res. 1991, 11, 28-34.
38. Paulis, L.; Simko, F. Blood pressure modulation and cardiovascular protection by melatonin: Potential mechanisms behind. Physiol. Res. 2007, 56, 671-684.
39. Lusardi, P.; Piazza, E.; Fogari, R. Cardiovascular effects of melatonin in hypertensive patients well controlled by nifedipine: A 24-h study. Br. J. Clin. Pharmacol. 2000, 49, 423-427.
40. Nelson, C. S.; Marino, J. L.; Allen, C. N. Melatonin receptors activate heteromeric G-protein coupled Kir3 channels. Neuroreport 1996, 7, 717-720.
41. Vanecek, J.; Klein, D. C. Sodium-dependent effects of melatonin on membrane potential of neonatal rat pituitary cells. Endocrinology 1992, 131, 939-946.
42. Benova, M.; Herichova, I.; Stebelova, K.; Paulis, L.; Krajcirovicova, K.; Simko, F.; Zeman, M. Effect of L-NAME-induced hypertension on melatonin receptors and melatonin evels in the pineal gland and the peripheral organs of rats. Hypertens. Res. 2009, 32, 242-247.
43. Schepelmann, M.; Molcan, L.; Uhrova, H.; Zeman, M.; Ellinger, I. The presence and localization of melatonin receptors in the rat aorta. Cell. Mol. Neurobiol. 2011, 31, 1257-1265.
44. Barta, A.; Parohova, J.; Vranková, S.; Janega, P.; Kovacsova, M.; Pechanova, O. The effects of melatonin on morphology of cardiovascular system in experimental metabolic syndrome. In Circulation, Proceedings of World Congress of Cardiology Scientific Sessions, Dubai, United Arab Emirates, 18-21 April 2012; Volume 125, p. E913.
45. 2 melatonin receptors are present and functional in rat caudal artery. J. Pharmacol. Exp. Ther. 2002, 302, 1295-1302.
46. 2 receptors mediate the inhibitory effects of melatonin on nitric oxide-induced relaxation of porcine isolated coronary arteries. J. Pharmacol. Exp. Ther. 2011, 336, 127-133.
47. Yang, Q.; Scalbert, E.; Delagrange, P.; Vanhoutte, P. M.; O'Rourke, S. T. Melatonin potentiates contractile responses to serotonin in isolated porcine coronary arteries. Am. J. Physiol. Heart Circ. Physiol. 2001, 280, H76-H82.
48. Malpaux, B.; Migaud, M.; Tricoire, H.; Chemineau, P. Biology of mammalian photoperiodism and the critical role of the pineal gland and melatonin. J. Biol. Rhythms 2001, 16, 336-347.
49. Vanĕcek, J.; Janský, L. Short days induce changes in specific melatonin binding in hamster median eminence and anterior pituitary. Brain Res. 1989, 477, 387-390.
50. 125I]iodomelatonin binding sites in Djungarian hamster brain. Endocrinology 1989, 125, 1011-1018.
51. Williams, L. M.; Hannah, L. T.; Hastings, M. H.; Maywood, E. S. Melatonin receptors in the rat brain and pituitary. J. Pineal Res. 1995, 19, 173-177.
52. Menendez-Pelaez, A.; Reiter, R. J. Distribution of melatonin in mammalian tissues: The relative importance of nuclear versus cytosolic localization. J. Pineal Res. 1993, 15, 59-69.
53. Benitez-King, G.; Anton-Tay, F. Calmodulin mediates melatonin cytoskeletal effects. Experientia 1993, 49, 635-641.
54. Pandi-Perumal, S. R.; Trakht, I.; Srinivasan, V.; Spence, D. W.; Maestroni, G. J.; Zisapel, N.; Cardinali, D. P. Physiological effects of melatonin: Role of melatonin receptors and signal transduction pathways. Prog. Neurobiol. 2008, 85, 335-353.
55. Pechanova, O.; Zicha, J.; Paulis, L.; Zenebe, W.; Dobesova, Z.; Kojsova, S.; Jendekova, L.; Sladkova, M.; Dovinova, I.; Simko, F.; et al. The effect of N-acetylcysteine and melatonin in adult spontaneously hypertensive rats with established hypertension. Eur. J. Pharmacol. 2007, 561, 129-136.
56. Paulis, L.; Pechanova, O.; Zicha, J.; Barta, A.; Gardlik, R.; Celec, P.; Kunes, J.; Simko, F. Melatonin interactions with blood pressure and vascular function during L-NAME-induced hypertension. J. Pineal Res. 2010, 48, 102-108.
57. Paulis, L.; Pechanova, O.; Zicha, J.; Liskova, S.; Celec, P.; Mullerova, M.; Kollar, J.; Behuliak, M.; Kunes, J.; Adamcova, M.; et al. Melatonin improves the restoration of endothelium-derived constricting factor signalling and inner diameter in the rat femoral artery after cessation of L-NAME treatment. J. Hypertens. 2010, 28, S19-S24.
58. Simko, F.; Pechanova, O.; Pelouch, V.; Krajcirovicova, K.; Mullerova, M.; Bednarova, K.; Adamcova, M.; Paulis, L. Effect of melatonin, captopril, spironolactone and simvastatin on blood pressure and left ventricular remodelling in spontaneously hypertensive rats. J. Hypertens. 2009, 27, S5-S10.
59. Simko, F.; Pechanova, O.; Pelouch, V.; Krajcirovicova, K.; Celec, P.; Palffy, R.; Bednarova, K.; Vrankova, S.; Adamcova, M.; Paulis, L. Continuous light and L-NAME-induced left ventricular remodelling: Different protection with melatonin and captopril. J. Hypertens. 2010, 28, S13-S18.
60. Koziróg, M.; Poliwczak, A. R.; Duchnowicz, P.; Koter-Michalak, M.; Sikora, J.; Broncel, M. Melatonin treatment improves blood pressure, lipid profile, and parameters of oxidative stress in patients with metabolic syndrome. J. Pineal Res. 2011, 50, 261-266.
61. Tan, D. X.; Manchester, L. C.; Reiter, R. J.; Qi, W.; Kim, S. J.; El-Sokkary, G. H. Ischemia/reperfusion-induced arrhythmias in the isolated rat heart: Prevention by melatonin. J. Pineal Res. 1998, 25, 184-191.
62. Tan, D. X.; Manchester, L. C.; Terron, M. P.; Flores, L. J.; Reiter, R. J. One molecule, many derivatives: A never-ending interaction of melatonin with reactive oxygen and nitrogen species? J. Pineal Res. 2007, 42, 28-42.
63. Tan, D. X.; Manchester, L. C.; Reiter, R. J.; Qi, W. B.; Karbownik, M.; Calvo, J. R. Significance of melatonin in antioxidative defense system: Reactions and products. Biol. Signals Recept. 2000, 9, 137-159.
64. Reiter, R. J.; Tan, D. X.; Jou, M. J.; Korkmaz, A.; Manchester, L. C.; Paredes, S. D. Biogenic amines in the reduction of oxidative stress: Melatonin and its metabolites. Neuro Endocrinol. Lett. 2008, 29, 391-398.
65. Van Marke de Lumen, K.; Kedziora-Kornatowska, K.; Czuczejko, J.; Szewczyk-Golec, K.; Pawluk, H.; Motyl, J.; Kornatowski, T.; Kedziora, J. Time dependent effect of melatonin administration on lipid peroxidation, superoxide dismutase activity and melatonin concentration in the elderly patients with essential arterial hypertension. Przegl. Lek. 2008, 65, 273-276.
66. Tamura, E. K.; Cecon, E.; Monteiro, A. W.; Silva, C. L.; Markus, R. P. Melatonin inhibits LPS-induced NO production in rat endothelial cells. J. Pineal Res. 2009, 46, 268-274.
67. Wurtman, R. J.; Axelord, J.; Chu, E. W. The relation between melatonin, a pineal substance, and the effects of light on the rat gonad. Ann. N. Y. Acad. Sci. 1964, 117, 228-230.
68. Moore, R. Y. Neural control of the pineal gland. Behav. Brain Res. 1996, 73, 125-130.
69. Dubocovich, M. L.; Cardinali, D. P.; Guardiola-Lemaitre, B.; Hagan, R. M.; Krause, D. N.; Sugden, D.; Vanhoutte, P. M.; Yocca, F. D. Melatonin receptors. In The IUPHAR Compendium of Receptor Characterization and Classification; Media: London, UK, 1998; pp. 187-193.
70. Kalsbeek, A.; Garidou, M. L.; Palm, I. F.; van Der Vliet, J.; Simonneaux, V.; Pevet, P.; Buijs, R. M. Melatonin sees the light: Blocking GABA-ergic transmission in the paraventricular nucleus induces daytime secretion of melatonin. Eur. J. Neurosci. 2000, 12, 3146-3154.
71. Klein, D. C.; Sugden, D.; Weller, J. L. Postsynaptic alpha-adrenergic receptors potentiate the β-adrenergic stimulation of pineal serotonin N-acetyltransferase. Proc. Natl. Acad. Sci. USA 1983, 80, 599-603.
72. Reiter, R. J. Pineal melatonin: Cell biology of its synthesis and of its physiological interactions. Endocr. Rev. 1991, 12, 151-180.
73. Ribelayga, C.; Pevet, P.; Simonneaux, V. Adrenergic and peptidergic regulations of hydroxyindole-O-methyltransferase activity in rat pineal gland. Brain Res. 1997, 777, 247-501.
74. Schomerus, C.; Korf, H. W. Mechanisms regulating melatonin synthesis in the mammalian pineal organ. Ann. N. Y. Acad. Sci. 2005, 1057, 372-383.
75. Cecon, E.; Fernandes, P. A.; Pinato, L.; Ferreira, Z. S.; Markus, R. P. Daily variation of constitutively activated nuclear factor kappa B (NFKB) in rat pineal gland. Chronobiol. Int. 2010, 27, 52-67.
76. Wang, M.; Yokotani, K.; Nakamura, K.; Murakami, Y.; Okada, S.; Osumi, Y. Melatonin inhibits the central sympatho-adrenomedullary outflow in rats. Jpn. J. Pharmacol. 1999, 81, 29-33.
77. K-Laflamme, A.; Wu, L.; Foucart, S.; de Champlain, J. Impaired basal sympathetic tone and α1-adrenergic responsiveness in association with the hypotensive effect of melatonin in spontaneously hypertensive rats. Am. J. Hypertens. 1998, 11, 219-229.
78. Chuang, J. I.; Chen, S. S.; Lin, M. T. Melatonin decreases brain serotonin release, arterial pressure and heart rate in rats. Pharmacology 1993, 47, 91-97.
79. Girouard, H.; Chulak, C. H.; Lejossec, M.; Lamontagne, D.; de Champlain, J. Chronic antioxidant treatment improves sympathetic functions and β-adrenergic pathway in the spontaneously hypertensive rats. J. Hypertens. 2003, 21, 179-188.
80. Girouard, H.; Denault, C.; Chulak, C.; de Champlain, J. Treatment by N-acetylcysteine and melatonin increases cardiac baroreflex and improves antioxidant reserve. Am. J. Hypertens. 2004, 17, 947-954.
81. Arangino, S.; Cagnacci, A.; Angiolucci, M.; Vacca, A. M.; Longu, G.; Volpe, A.; Melis, G. B. Effects of melatonin on vascular reactivity, catecholamine levels, and blood pressure in healthy men. Am. J. Cardiol. 1999, 83, 1417-1419.
82. Yildiz, M.; Sahin, B.; Sahin, A. Acute effects of oral melatonin administration on arterial distensibility, as determined by carotid-femoral pulse wave velocity, in healthy young men. Exp. Clin. Cardiol. 2006, 11, 311-313.
83. Tengattini, S.; Reiter, R. J.; Tan, D. X.; Terron, M. P.; Rodella, L. F.; Rezzani, R. Cardiovascular diseases: Protective effects of melatonin. J. Pineal Res. 2008, 44, 16-25.
84. Simko, F.; Pechanova, O. Potential roles of melatonin and chronotherapy among the new trends in hypertension treatment. J. Pineal Res. 2009, 47, 127-133.
85. Cardinali, D. P.; Srinivasan, V.; Brzezinski, A.; Brown, G. M. Melatonin and its analogs in insomnia and depression. J. Pineal Res. 2012, 52, 365-375.
86. G-nitro-L-arginine-methyl ester hypertensive rats. J. Hypertens. Suppl. 2009, 27, S11-S16.
87. Cagnacci, A.; Cannoletta, M.; Renzi, A.; Baldassari, F.; Arangino, S.; Volpe, A. Prolonged melatonin administration decreases nocturnal blood pressure in women. Am. J. Hypertens. 2005, 18, 1614-1618.
88. Reppert, S. M.; Weaver, D. R.; Rivkees, S. A.; Stopa, E. G. Putative melatonin receptors in a human biological clock. Science. 1988, 242, 78-81.
89. Patel, K. P.; Li, Y. F.; Hiroka, Y. Role of nitric oxide in central sympathetic outflow. Exp. Biol. Med. 2001, 226, 814-824.
90. A receptor mediates the hypnotic activity of melatonin in rats. Pharmacol. Biochem. Behav. 2003, 74, 573-578.
91. Rossi, N. F.; Black, S. M.; Telemaque-Potts, S.; Chen, H. Neuronal nitric oxide synthase activity in the paraventricular nucleus buffers central endothelin-1-induced pressor response and vasopressin secretion. J. Cardiovasc. Pharmacol. 2004, 44, S283-S288.
92. Irmak, M. K.; Sizlan, A. Essential hypertension seems to result from melatonin-induced epigenetic modifications in area postrema. Med. Hypotheses. 2006, 66, 1000-1007.
93. Xia, C. M.; Shao, C. H.; Xin, L.; Wang, Y. R.; Ding, C. N.; Wang, J.; Shen, L. L.; Li, L.; Cao, Y. X.; Zhu, D. N. Effects of melatonin on blood pressure in stress-induced hypertension in rats. Clin. Exp. Pharmacol. Physiol. 2008, 35, 1258-1264.
94. A receptors. Clin. Exp. Pharmacol. Physiol. 2009, 36, 436-440.
95. Witte, K.; Schnecko, A.; Buijs, R. M.; van der Vliet, J.; Scalbert, E.; Delagrange, P.; Guardiola-Lemaître, B.; Lemmer, B. Effects of SCN lesions on circadian blood pressure rhythm in normotensive and transgenic hypertensive rats. Chronobiol. Int. 1998, 15, 135-145.
96. Zeman, M.; Szantoova, K.; Stebelova, K.; Mravec, B.; Herichova, I. Effect of rhythmic melatonin administration on clock gene expression in the suprachiasmatic nucleus and the heart of hypertensive TGR(mRen2)27 rats. J. Hypertens. 2009, 27, S21-S26.
97. Lau, F. C.; Shukitt-Hale, B.; Joseph, J. A. The beneficial effects of fruit polyphenols on brain aging. Neurobiol. Aging 2005, 26, 128-132.
98. Kotler, M.; Rodríguez, C.; Sáinz, R. M.; Antolín, I.; Menéndez-Peláez, A. Melatonin increases gene expression for antioxidant enzymes in rat brain cortex. J. Pineal Res. 1998, 24, 83-89.
99. Zhou, J.; Zhang, S.; Zhao, X.; Wei, T. Melatonin impairs NADPH oxidase assembly and decreases superoxide anion production in microglia exposed to amyloid-β1-42. J. Pineal Res. 2008, 45, 157-165.
100. Haulică, I. Experimental evidence on pineal renin-angiotensin system as activator of serotonin and melatonin synthesis. Rev. Med. Chir. Soc. Med. Nat. Iasi. 1991, 95, 293-296.
101. Carrera, M. P.; Ramírez-Expósito, M. J.; Valenzuela, M. T.; Dueñas, B.; García, M. J.; Mayas, M. D.; Martínez-Martos, J. M. Renin-angiotensin system-regulating aminopeptidase activities are modified in the pineal gland of rats with breast cancer induced by-methyl-nitrosourea. Cancer Investig. 2006, 24, 149-153.
102. Mohan, N.; Sadeghi, K.; Reiter, R. J.; Meltz, M. L. The neurohormone melatonin inhibits cytokine, mitogen and ionizing radiation induced NF-κB. Biochem. Mol. Biol. Int. 1995, 37, 1063-1070.
103. Reiter, R. J.; Calvo, J. R.; Karbownik, M.; Qi, W.; Tan, D. X. Melatonin and its relation to the immune system and inflammation. Ann. N. Y. Acad. Sci. 2000, 917, 376-386.
104. Mauriz, J. L.; Collado, P. S.; Veneroso, C.; Reiter, R. J.; González-Gallego, J. A review of the molecular aspects of melatonin's anti-inflammatory actions: Recent insights and new perspectives. J. Pineal Res. 2013, 54, 1-14.
105. Pozo, D.; Reiter, R. J.; Calvo, J. R.; Guerrero, J. M. Inhibition of cerebellar nitric oxide synthase and cyclic GMP production by melatonin via complex formation with calmodulin. J. Cell. Biochem. 1997, 65, 430-442.
106. Koh, P. O. Melatonin regulates nitric oxide synthase expression in ischemic brain injury. J. Vet. Med. Sci. 2008, 70, 747-750.
107. Tain, Y. L.; Leu, S.; Wu, K. L.; Lee, W. C.; Chan, J. Y. Melatonin prevents maternal fructose intake-induced programmed hypertension in the offspring: Roles of nitric oxide and arachidonic acid metabolites. J. Pineal Res. 2014, 57, 80-89.
108. Reiter, R. J; Tan, D. X; Korkmaz, A. The circadian melatonin rhythm and its modulation: Possible impact on hypertension. J. Hypertens. Suppl. 2009, 27, S17-S20.
109. White, W. B. Relating cardiovascular risk to out-of-office blood pressure and the importance of controlling blood pressure 24 hours a day. Am. J. Med. 2008, 121, S2-S7.
110. Ohkubo, T.; Imai, Y.; Tsuji, I.; Nagai, K.; Watanabe, N.; Minami, N.; Kato, J.; Kikuchi, N.; Nishiyama, A.; Aihara, A.; et al. Relation between nocturnal decline in blood pressure and mortality. The Ohasama Study. Am. J. Hypertens. 1997, 11, 1201-1207.
111. Hermida, R. C.; Ayala, D. E.; Mojón, A.; Fernández, J. R. Decreasing sleep-time blood pressure determined by ambulatory monitoring reduces cardiovascular risk. J. Am. Coll. Cardiol. 2011, 58, 1165-1173.
112. Hermida, R. C.; Ayala, D. E.; Mojón, A.; Fernández, J. R. Influence of circadian time of hypertension treatment on cardiovascular risk: Results of the MAPEC study. Chronobiol. Int. 2010, 27, 1629-1651.
113. Scheer, F. A.; van Montfrans, G. A.; van Someren, E. J.; Mairuhu, G.; Buijs, R. M. Daily nighttime melatonin reduces blood pressure in male patients with essential hypertension. Hypertension 2004, 43, 192-197.
114. Jonas, M.; Garfinkel, D.; Zisapel, N.; Laudon, M.; Grossman, E. Impaired nocturnal melatonin secretion in non-dipper hypertensive patients. Blood Press 2003, 12, 19-24.
115. Zeman, M.; Dulková, K.; Bada, V.; Herichová, I. Plasma melatonin concentrations in hypertensive patients with the dipping and non-dipping blood pressure profile. Life Sci. 2005, 76, 1795-1803.
116. Holmes, S. W.; Sugden, D. Proceedings: The effect of melatonin on pinealectomy-induced hypertension in the rat. Br. J. Pharmacol. 1976, 56, 360P-361P.
117. Brown, G. M.; Bar-Or, A.; Grossi, D.; Kashur, S.; Johannson, E.; Yie, S. M. Urinary 6-sulphatoxymelatonin, an index of pineal function in the rat. J. Pineal Res. 1991, 10, 141-147.
118. Chik, C. L.; Talalla, A.; Brown, G. M. Effect of pinealectomy on serum melatonin, luteinizing hormone and prolactin: A case report. Clin. Endocrinol. 1985, 23, 367-372.
119. Stieglitz, A.; Spiegelhalter, F.; Klante, G.; Heldmaier, G. Urinary 6-sulphatoxymelatonin excretion reflects pineal melatonin secretion in the Djungarian hamster (Phodopus sungorus). J. Pineal Res. 1995, 18, 69-76.
120. Simko, F.; Pechanova, O.; Repova Bednarova, K.; Krajcirovicova, K.; Celec, P.; Kamodyova, N.; Zorad, S.; Kucharska, J.; Gvozdjakova, A.; Adamcova, M.; et al. Hypertension and cardiovascular remodelling in rats exposed to continuous light: Protection by ACE-inhibition and melatonin. Mediators Inflamm. 2014, 2014, 703175.
121. Grossman, E.; Laudon, M.; Yalcin, R.; Zengil, H.; Peleg, E.; Sharabi, Y.; Kamari, Y.; Shen-Orr, Z.; Zisapel, N. Melatonin reduces night blood pressure in patients with nocturnal hypertension. Am. J. Med. 2006, 119, 898-902.
122. Cagnacci, A.; Elliott, J. A.; Yen, S. S. Melatonin: A major regulator of the circadian rhythm of core temperature in humans. J. Clin. Endocrinol. Metab. 1992, 75, 447-452.
123. Nakano, Y.; Oshima, T.; Ozono, R.; Higashi, Y.; Sasaki, S.; Matsumoto, T.; Matsuura, H.; Chayama, K.; Kambe, M. Non-dipper phenomenon in essential hypertension is related to blunted nocturnal rise and fall of sympatho-vagal nervous activity and progress in retinopathy. Auton. Neurosci. 2001, 88, 181-186.
124. Goncharuk, V. D.; van Heerikhuize, J.; Dai, J. P.; Swaab, D. F.; Buijs, R. M. Neuropeptide changes in the suprachiasmatic nucleus in primary hypertension indicate functional impairment of the biological clock. J. Comp. Neurol. 2001, 431, 320-330.
125. Goncharuk, V. D.; van Heerikhuize, J.; Swaab, D. F.; Buijs, R. M. Paraventricular nucleus of the human hypothalamus in primary hypertension: Activation of corticotropin-releasing hormone neurons. J. Comp. Neurol. 2002, 443, 321-331.
126. Escames, G.; Khaldy, H.; León, J.; González, L.; Acuña-Castroviejo, D. Changes in iNOS activity, oxidative stress and melatonin levels in hypertensive patients treated with lacidipine. J. Hypertens. 2004, 22, 629-635.
127. Dagnino-Subiabre, A.; Orellana, J. A.; Carmona-Fontaine, C.; Montiel, J.; Díaz-Velíz, G.; Serón-Ferré, M.; Wyneken, U.; Concha, M. L.; Aboitiz, F. Chronic stress decreases the expression of sympathetic markers in the pineal gland and increases plasma melatonin concentration in rats. J. Neurochem. 2006, 97, 1279-1287.